Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders

Gallelli, Luca (2011) Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders. Functional Neurology, 26 (S1). pp. 1-7. ISSN 1971-3274

PDF portiere.pdf - Published Version Restricted to Repository staff only Download (558kB)

Abstract

Dementia diseases are continuously increasing, with a prevalence of 4/6 million of new cases per year worldwide. The majority of patients live in developed countries, where survival into old age is quite common. However, the forecast growth rate of dementia patients is three times higher in India, China and neighboring countries in South Asia and the Western Pacific. Modulation of acetylcholine neurotransmission is a therapeutic approach to dementia when the cholinergic neurons do not present major damage. The different molecules used to enhance central cholinergic tone are: cholinergic precursors, acetylcholine esterase inhibitors, nicotinic receptor agonists and M2 receptor antagonists. Among the cholinergic precursors, the semi-synthetic compound choline alphoscerate has emerged as a valid therapeutic approach for the treatment of cognitive impairment in neurological patients. Several studies have shown that choline alphoscerate is able to increase the synthesis and the release of acetylcholine in patients with Alzheimer-related dementia, cerebrovascular damage and aging. Moreover, preliminary evaluations suggest a useful role for choline alphoscerate in patients with cognitive impairment of varying severity related to brain trauma or to Parkinson’s disease. Literature data suggest that, in these conditions, choline alphoscerate shows a better efficacy than other cholinergic precursors (choline, lecithin, phosphatidylserine and citocoline) and also has a good tolerability and safety profile. In adult-onset dementia, it could be a therapeutic resource, either in association with the newer acetylcholine esterase inhibitors or as a monotherapy in patients in whom these inhibitors are not tolerated or are contraindicated.

Item Type:	Article
Uncontrolled Keywords:	choline alphoscerate, citicoline, cholinergic system, cognitive dysfunction, dementia
Subjects:	600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 615 Farmacologia e terapeutica 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 615 Farmacologia e terapeutica > 615.7 Farmacodinamica 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) > 616.8 Malattie del sistema nervoso e disturbi mentali (Classificare qui la Neuropsichiatria, la Neurologia)
Depositing User:	Danilo Dezzi
Date Deposited:	07 Nov 2011 18:51
Last Modified:	03 Feb 2016 09:47
URI:	http://eprints.bice.rm.cnr.it/id/eprint/3508

Actions (login required)

View Item